Low-dose peginterferon used for hepatitis C doesn’t work
Scientists at St. Jude Children’s Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza. They found that the antibiotics clindamycin and azithromycin, which kill bacteria by inhibiting their protein synthesis, are more effective than a standard first-line treatment with the “beta-lactam” antibiotic ampicillin, which causes the bacteria to lyse, or burst.
Full Post: Discovery of better treatment for bacterial pneumonia
An NIH funded multi-center clinical trial found no benefit from “maintenance therapy,” low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment.
In addition, the study showed a surprising health decline in patients with liver disease over the course of four years.
A Saint Louis University researcher was lead author and chairman of the study, which will be published in the Dec. 4 issue of the New England Journal of Medicine. The study ruled out low-dose peginterferon maintenance therapy as a treatment for patients with advanced chronic hepatitis.
“This course of treatment had been adopted by a number of doctors in the U.S. and in other countries, though it had yet to be proven to work. That practice should be stopped based on the results of this trial. There is no rationale for using maintenance therapy,” said Adrian Di Bisceglie, M.D., professor of internal medicine, chief of hepatology and co-director of the Liver Center at Saint Louis University. “The treatment is clearly ineffective.”
About 4 million people in the U.S. have been infected with hepatitis C; an estimated 10,000 to 12,000 people die from complications each year in this country. Hepatitis C is caused by a virus, transmitted by contact with blood, and may initially be asymptomatic. For patients who develop a chronic hepatitis C infection, inflammation of the liver may develop, leading to fibrosis and cirrhosis (scarring of the liver), as well as other complications including liver cancer and death.
For patients with chronic hepatitis C, the prognosis varies. About half fully recover after an initial course of peginterferon and ribavirin anti-viral therapy that may last from six months to a year.
The remaining patients, known as non-responders, may improve but the virus is not eliminated. Researchers studied these patients, looking at those with advanced liver disease as identified by liver biopsies that showed advanced scarring. These patients were at greatest risk for worsening.
The study looked at 1050 patients at 10 different clinical sites.
Researchers gave patients peginterferon for three and a half years, but in lower doses to try to suppress but not eliminate the virus, with the hope of slowing the dire consequences of liver disease. Half of the patients were treated with a low dose of peginterferon and half were put into a control group for a total of four years.
The results were clear; maintenance therapy did not stop liver disease from progressing.
In addition, researchers were startled by the rate of progression of liver disease. After four years, 30 percent of the patients in both the treatment and control groups had developed liver failure, liver cancer, or had died. Among those with milder cirrhosis, 10 to 12 percent developed severe liver disease, also unexpected.
“Hepatitis patients in these circumstances got very ill over the course of four years, surprisingly so,” said Di Bisceglie. “The lesson we learned is that once chronic hepatitis C gets to the stage of advanced fibrosis, patients can decline rapidly.”
As doctors look to the future, their hope rests on new drugs that are currently in clinical trials.
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology. Alcoholic hepatitis is a major cause of morbidity and mortality worldwide.
Full Post: Etanercept found to be ineffective in treating alcoholic hepatitis
A new study shows that infection with hepatitis C virus (HCV) increases a person’s risk for a highly fatal cancer of the biliary tree, the bile carrying pathway between the liver and pancreas. This finding is in the January issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American
Full Post: Infection with hepatitis C virus may increase pancreatic cancer risk
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program. Under the terms of the collaboration, Bristol-Myers Squibb agreed to pay ZymoGenetics an upfront cash payment of $85 million for the
Full Post: Bristol-Myers Squibb and ZymoGenetics to collaborate on hepatitis C compound
A new £1m clinical research facility dedicated to tackling liver disease, the fifth most common cause of death in the UK, opens today at Imperial College London. Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical
Full Post: Liver disease tackled with dedicated unit at Imperial College London
Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis C virus (HCV), say researchers from the University of Leeds. A study of a protein called p7, has revealed that differences in the genetic coding of the protein between virus strains - known as genotypes - alter the
Full Post: Potential new therapy for hepatitis C treatment